Clinical Trials for GBA1 Parkinson's
Changes in the GBA1 gene (often just called GBA) are among the most common genetic risk factors for Parkinson's. They affect an enzyme called glucocerebrosidase, which helps brain cells clear waste, and several treatments now in trials aim to boost that enzyme's activity.
Some of these studies enroll only people with a confirmed GBA1 change, while others test drugs — such as ambroxol — designed to work through this pathway. Knowing your genetic status can open the door to trials that would not otherwise be available.
Below are the recruiting trials we track that involve GBA1 Parkinson's. Sign up to be emailed when a new one opens.
11 Recruiting GBA1 Parkinson's Trials
- Improve walking and reduce stiffness, NCT07572071, PHASE1, RECRUITING
- Determine cancer risk in Parkinson, NCT06814431, RECRUITING
- Predict symptoms and personalize care, NCT03523065, RECRUITING
- Restore glucocerebrosidase activity in putamen, NCT05565443, RECRUITING
- Find drugs boosting cell cleanup, NCT05536388, RECRUITING
- Slow Parkinson degeneration using Dserine, NCT07312110, PHASE2, RECRUITING
- Identify markers predicting Parkinson progression, NCT02305147, RECRUITING
- New drug slows Parkinson progression, NCT06732180, PHASE1, RECRUITING
- Identify candidates for gene therapy, NCT06151002, RECRUITING
- Identify tests predicting Parkinson progression, NCT04477785, RECRUITING
- Detect early Parkinson brain changes, NCT04101968, RECRUITING